読み込み中
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
前日終値
$2.03
+$0.04 · +2.01%
日中の時刻はETです。市場データは遅延する場合があります。
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
日中レンジ
現在 $2.03
52週レンジ
現在 $2.03
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
36
割高
センチメント
72
強気
リスク
71
高リスク
モメンタム
65
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
日中レンジ
現在 $2.03
52週レンジ
現在 $2.03
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1385.8万 USD | 1614.6万 USD | — | — | — |
| 売上原価 | 238.8万 USD | 47.5万 USD | — | — | — |
| 粗利益 | 1147万 USD | 1567.1万 USD | — | — | — |
| 研究開発 | 7369.6万 USD | 5874.7万 USD | 4958.6万 USD | 8612.9万 USD | 5105.4万 USD |
| 販売・一般管理 | 2219.4万 USD | 2542万 USD | 3261万 USD | 3735.2万 USD | 1866.3万 USD |
| 営業費用 | 9589万 USD | 1.05億 USD | 8219.6万 USD | 1.23億 USD | 6971.7万 USD |
| 受取利息 | 361万 USD | 703.9万 USD | 663万 USD | 276.4万 USD | 2.3万 USD |
| 減価償却費と償却費 | 451.1万 USD | 298.2万 USD | 192.7万 USD | 70.9万 USD | 64.7万 USD |
| 営業利益 | −8442万 USD | −8946万 USD | −8219.6万 USD | −1.23億 USD | −6971.7万 USD |
| 純利益 | −7962.1万 USD | −7733.1万 USD | −7379万 USD | −1.21億 USD | −7597.5万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI522.3万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF194.46万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB105.25万0.01%108.2億 USD0.44%$206.49+3.00%
iShares Micro-Cap ETFIWC30.6万0.02%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM19万0.16%1.17億 USD0.73%$15.9402+0.25%
Invesco Nasdaq Biotechnology ETFIBBQ1.26万0.01%1.12億 USD0.19%$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB6504.120.01%9320.36万 USD1.19%$110.98+5.68%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
